- Colcrys, a plant-derived medication, has been recognized by the FDA for successfully treating acute gout and Familial Mediterranean Fever (FMF), both of which are inflammatory disorders.
- The FDA’s approval of Colcrys is part of an ongoing initiative to regulate other similar, yet unapproved, pharmaceutical products.
- As a result of the research leading to Colcrys’ approval, a revised, lower dosing regimen has been suggested by the FDA to avoid potential gastrointestinal issues. This important information has been communicated to healthcare professionals.
- Colcrys has now become an FDA-endorsed medication for managing FMF – a condition more prevalent in Mediterranean countries, but less common in the United States.
- The development and production of Colcrys are carried out by the Philadelphia-based company, Mutual Pharmaceutical Company Inc.
Colcrys, a medication derived from the autumn crocus plant, has been recognized by the U.S. Food and Administration for its effectiveness in treating acute gout and Familial Mediterranean Fever (FMF). These two conditions are known for being inflammatory disorders that cause a range of uncomfortable symptoms.
For a substantial period, colchicine, the active ingredient in Colcrys, has been utilized to counteract acute gout attacks, even though it lacked official FDA endorsement. This move to approve Colcrys forms part of the FDA’s ongoing initiative to regulate other similar, yet unapproved, pharmaceutical products.
A Smarter Dosing Approach
One of the key outcomes from the research that led to Colcrys’ approval was the suggestion for a revised dosing regimen. The FDA has recommended a lower dosage for Colcrys than what was previously prescribed to prevent potential gastrointestinal issues.
Alongside this, the FDA has provided critical information to healthcare professionals about the lower dosing schedule for Colcrys. The organization also highlighted the possibility of severe interactions between Colcrys and other medications.
Colcrys and Familial Mediterranean Fever
Familial Mediterranean Fever (FMF) is a condition typically seen in Mediterranean countries, although it is less prevalent in the United States. People suffering from FMF experience symptoms such as arthritis, fever, and inflammation in the lungs and abdomen. With the approval of Colcrys by the FDA, there is now an FDA-endorsed medication available for managing FMF.
The development and production of Colcrys are undertaken by the Philadelphia-based Mutual Pharmaceutical Company Inc.
For further insights about this medication and its approval, please visit the FDA’s official website through the following here.